The second advantage is the application of our designed compound in combination with bcr‐abl inhibitors, such as nilotinib, in the treatment of chronic myelogenous leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.